Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).

Date publication

octobre 2021

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Benhaim L, Bouché O, Normand C, Didelot A, Mulot C, Le Corre D, Garrigou S, Djadi-Prat J, Wang-Renault SF, Perez-Toralla K, Pekin D, Poulet G, Landi B, Taieb J, Selvy M, Emile JF, Lecomte T, Blons H, Chatellier G, Link DR, Taly V, Laurent-Puig P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34731746

Résumé

In non-metastatic colorectal cancer (CRC), we evaluated prospectively the pertinence of longitudinal detection and quantification of circulating tumor DNA (ctDNA) as a prognostic marker of recurrence.

Mots clés

Circulating tumor DNA, Colorectal cancer, Liquid biopsy, Methylated DNA, Picodroplet droplet-based digital PCR, Prognostic marker

Référence

Eur J Cancer. 2021 Oct 30;159:24-33